American Society of Hematology

Figure 2

$Figure 2. Effect of tipifarnib (R115777) on FTase-dependent processing of HDJ-2 in leukemic bone marrow samples. Heparinized bone marrow aspirates on day 0 (prior to tipifarnib treatment) and day 8 of therapy were fractionated on 2-step Ficoll-Hypaque gradients. Mononuclear cells were washed once with RPMI 1640 containing 10 nM HEPES (pH 7.4 at room temperature), counted, and solubilized for immunoblotting. Aliquots containing 50 μg total cellular protein were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with monoclonal anti–HDJ-2 (Neomarkers, Fremont, CA). K562 cells treated with diluent or tipifarnib (R115777) served as negative and positive controls, respectively, for the presence of pre–HDJ-2.$

Effect of tipifarnib (R115777) on FTase-dependent processing of HDJ-2 in leukemic bone marrow samples. Heparinized bone marrow aspirates on day 0 (prior to tipifarnib treatment) and day 8 of therapy were fractionated on 2-step Ficoll-Hypaque gradients. Mononuclear cells were washed once with RPMI 1640 containing 10 nM HEPES (pH 7.4 at room temperature), counted, and solubilized for immunoblotting. Aliquots containing 50 μg total cellular protein were subjected to SDS-PAGE, transferred to nitrocellulose, and probed with monoclonal anti–HDJ-2 (Neomarkers, Fremont, CA). K562 cells treated with diluent or tipifarnib (R115777) served as negative and positive controls, respectively, for the presence of pre–HDJ-2.

This Feature Is Available To Subscribers Only